Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study.

Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study. Abstract Text:

Maximilian Burger,Maximilian Burger,

Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study. Publishing Authors By Initials

M Burger,M Burger,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study. Journal Published:

PUBLICATION TYPE: Editorial

Journal: European urology

VOLUME: 52

Page Numbers: 1516-7

Journal Abbreviation: Eur. Urol.

ISSN: 0302-2838

DAY: 1

MONTH: Nov

YEAR: 2007

Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7512719

Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study.

AFFILIATION:

Country: Switzerland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Eur Urol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study Related Publications

• A framework and methods for incorporating gender-related issues in wildlife risk assessment: gender-related differences in metal levels and other contaminants as a case study.
• A model for selecting bioindicators to monitor radionuclide concentrations using Amchitka Island in the Aleutians as a case study.
• Assessment and management of risk to wildlife from cadmium.
• Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.
• Cancer stem cells and individualized therapy.
• Continuous-wave broadly tunable Cr(2+):ZnSe laser.
• Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study.
• Genomic and nongenomic effects of estrogen signaling in human endometrial cells: involvement of the growth factor receptor signaling downstream AKT pathway.
• Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
• Mixed effects modeling of weight change associated with placebo and pregabalin administration.
• Molecular analysis of xenograft models of human cancer cachexia--possibilities for therapeutic intervention.
• Monoclonal antibodies to guinea pig interferon-gamma: Tools for cytokine detection and neutralization.
• Not Available
• Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.
• Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
• Product update.
• Protective sustainability of ecosystems using Department of Energy buffer lands as a case study.
• Quantitative thin-layer chromatography of cobalamin complexes.
• Telomerase and its potential for therapeutic intervention.
• Telomerase in cancer diagnosis and therapy: a clinical perspective.
• The assessment of alexithymia in medical settings: implications for understanding and treating health problems.
• The effect on ecological systems of remediation to protect human health.
• Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
• Therapeutic implications of leukemic stem cell pathways.
• Treatment seeking for alcohol and drug use disorders by immigrants to the Netherlands: retrospective, population-based, cohort study.
• [Endothelioma as variety of tubular mesothelioma of the ovary.]
• [Horner's syndrome after fracture of the first rib]
• [New knowledge and experience with the urinary organs in pregnancy.]
• [Not Available.]
• [ON TRANSVERSE PRESENTATION.]